Bevacizumab Treatment After Surgery for Proliferative Diabetic Retinopathy A Study in Patients Undergoing Vitrectomy

What this Trial Is About

This research aims to evaluate the effects of immediate postoperative bevacizumab administration in patients with proliferative diabetic retinopathy undergoing vitrectomy surgery. The study focuses on individuals with type I or II diabetes who require surgery to address complications such as non-clearing vitreous hemorrhage, tractional retinal detachment, or fibrovascular proliferation affecting vision. The goal is to compare outcomes between those who receive bevacizumab right after surgery and those who do not. Participants will be randomly assigned to one of two groups one group will receive an injection of bevacizumab immediately after their vitrectomy, while the other group will not receive this treatment. The surgery involved is pars plana vitrectomy, performed to improve vision affected by the diabetic eye complications. This is a double-blind study, meaning neither the participants nor the researchers know who receives the drug or not during the trial. During the study, participants will be followed and assessed for six months after surgery. Researchers will monitor their vision using tests such as the best-corrected spectacle visual acuity on the Snellen chart. They will also evaluate the safety and effectiveness of the treatment, looking for any changes or complications. Participants will attend scheduled visits to support ongoing monitoring and outcome measurement over this period.

Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy